Altimmune (NASDAQ:ALT – Get Free Report) was downgraded by equities researchers at Wall Street Zen from a “sell” rating to a “strong sell” rating in a research note issued to investors on Saturday, Wall Street Zen reports.
Several other research firms also recently weighed in on ALT. Evercore reissued an “outperform” rating on shares of Altimmune in a research report on Wednesday, September 23rd. HC Wainwright reaffirmed a “buy” rating on shares of Altimmune in a report on Tuesday, July 28th. B. Riley Financial reaffirmed a “buy” rating on shares of Altimmune in a report on Friday. Citigroup reiterated a “market outperform” rating on shares of Altimmune in a research note on Friday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Altimmune in a report on Monday, September 21st. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $14.33.
Get Our Latest Stock Analysis on ALT
Altimmune Stock Performance
Altimmune stock opened at $1.65 on Friday. The stock has a 50-day moving average of $2.58 and a two-hundred day moving average of $3.15. The company has a debt-to-equity ratio of 0.08, a quick ratio of 23.93 and a current ratio of 23.93. Altimmune has a one year low of $1.58 and a one year high of $6.44. The stock has a market cap of $319.98 million, a PE ratio of -2.28 and a beta of 0.16.
Altimmune (NASDAQ:ALT – Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.02). On average, research analysts anticipate that Altimmune will post -0.58 EPS for the current fiscal year.
Insider Buying and Selling at Altimmune
In other news, CEO Jerome Durso acquired 30,700 shares of Altimmune stock in a transaction dated Friday, November 13th. The stock was purchased at an average cost of $1.62 per share, for a total transaction of $49,734.00. Following the completion of the purchase, the chief executive officer directly owned 93,200 shares in the company, valued at $150,984. This trade represents a 49.12% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders bought 50,700 shares of company stock valued at $82,334 over the last quarter. 1.60% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Altimmune
A number of large investors have recently bought and sold shares of ALT. Nantahala Capital Management LLC boosted its position in Altimmune by 14.7% in the third quarter. Nantahala Capital Management LLC now owns 1,720,000 shares of the company’s stock valued at $4,919,000 after buying an additional 220,000 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in Altimmune by 268.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,045,926 shares of the company’s stock worth $3,221,000 after buying an additional 762,223 shares during the period. Bank of New York Mellon Corp purchased a new position in Altimmune during the 2nd quarter worth approximately $2,097,000. Bank of America Corp DE raised its position in Altimmune by 48.6% during the 1st quarter. Bank of America Corp DE now owns 570,203 shares of the company’s stock worth $1,756,000 after buying an additional 186,420 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. raised its position in Altimmune by 156.5% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 518,198 shares of the company’s stock worth $1,575,000 after buying an additional 316,209 shares during the last quarter. Hedge funds and other institutional investors own 78.05% of the company’s stock.
Latest Altimmune News
Here’s some of the latest news about ALT:
- Positive Sentiment: Newly published 48-week Phase 2b IMPACT results showed pemvidutide improved non-invasive measures of liver fat, inflammation, and fibrosis, alongside weight loss and generally favorable tolerability. The findings support the ongoing Phase 3 PERFORMA MASH trial, though pemvidutide remains investigational. Trial results article
- Neutral Sentiment: B. Riley reaffirmed its Buy rating, providing supportive analyst sentiment, although the rating is not a guarantee of future performance.
- Negative Sentiment: A Seeking Alpha analysis characterized pemvidutide’s development as late and capital-intensive, underscoring the risk that lengthy trials and spending could weigh on ALT before any potential product revenue. Analysis
About Altimmune
Altimmune, Inc. is a clinical-stage biopharmaceutical company developing peptide-based treatments for obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland. Its lead candidate, pemvidutide, is an investigational medicine that activates GLP-1 and glucagon receptors. Altimmune has studied the drug for obesity and metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. Altimmune’s work focuses on advancing treatments through clinical development; pemvidutide is not an approved medicine.
See Also
- Five stocks we like better than Altimmune
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Altimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altimmune and related companies with MarketBeat.com's FREE daily email newsletter.
